Objective
This study aimed to see how well cariprazine helps reduce anxiety symptoms in adults diagnosed with major depressive disorder (MDD) who did not respond well to other antidepressants.
Methods
We looked at data from a large study with 751 participants. We focused on how cariprazine at doses of 1.5 mg and 3.0 mg per day affected both depression and anxiety over six weeks.
Results
At the end of six weeks, patients taking cariprazine along with their usual antidepressant showed more improvement in their depression compared to those taking a placebo, especially those who started with higher anxiety levels. Specifically:
- For patients with high anxiety, cariprazine 1.5 mg/day improved depression scores by an average of 2.4 points more than placebo.
- Cariprazine also significantly reduced anxiety symptoms overall, with reductions in anxiety scores of 0.8 points for the 1.5 mg dose and 0.5 points for the 3.0 mg dose.
Conclusions
Cariprazine may help reduce both depression and anxiety symptoms in patients with MDD, regardless of their initial anxiety levels.
Next Steps for Clinics
- Define Measurable Outcomes: Set clear goals for how to measure the effectiveness of cariprazine in treating anxiety in patients with MDD.
- Select AI Tools: Choose AI solutions that can assist in tracking patient outcomes and improving treatment plans.
- Implement Gradually: Start with a small pilot project to monitor how well these solutions work in practice.
Contact Us for AI Solutions in Medical Management
For more information, reach out to us:
